Loading...
Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: thromboembolic events in the randomized CASSINI Trial
Khorana, A. A. McNamara, Mairead G Kakkar, A. K. Streiff, M. B. Riess, H. Vijapurkar, U. Kaul, S. Wildgoose, P. Soff, G. A.
Khorana, A. A.
McNamara, Mairead G
Kakkar, A. K.
Streiff, M. B.
Riess, H.
Vijapurkar, U.
Kaul, S.
Wildgoose, P.
Soff, G. A.
Citations
Altmetric:
Abstract
Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were not included in the primary analysis. This study was aimed to evaluate the full impact of rivaroxaban thromboprophylaxis on all prespecified thromboembolic endpoints occurring on study. Methods CASSINI was a double-blind, randomized, placebo-controlled study in adult ambulatory patients with cancer at risk for VTE (Khorana score /=2). Patients were screened at baseline for deep-vein thrombosis (DVT) and randomized if none was found. The primary efficacy endpoint was a composite of lower extremity proximal DVT
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 175.24 KB
Keywords
Type
Article
Citation
A. A. Khorana, M. G. McNamara, A. K. Kakkar et al. Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. TH Open. 2020;4(2):e107-e112.